People and Business News — 12/22
People News
Worldwide Clinical Trials announced the appointment of Pete Duprat as Senior Vice President, Commercial, Early Phase.
IDDI announced the appointment of a new CEO, Linda Danielson.
Signant Health announced the appointment of Graciela Racaro to the position of chief operating officer.
CluePoints, has announced Andy Cooper has been appointed as its new Chief Executive Officer.
Veeva Systems and CDISC announce that Dan Crawford, Veeva Clinical Database principal consultant, has been elected chair of the CDISC Advisory Council.
Emmes announced that Ching Tian has joined the company as chief innovation officer Additonally the comapny has hired Wendy Buckland as Chief Operating Officer.
Business News
Quanticate announced plans for further expansion and new jobs in 2023 as it thrives post-pandemic.
physIQ announced that OncoBay Clinical, Inc., has joined the Intrepid Partner Program.
Catalent announced that it has completed the expansion of its clinical supply facility in the Waigaoqiao Free Trade Zone in Shanghai, China.
Almac Clinical Technologies has been ranked as the industry’s most preferred IRT application globally, among recent users in a recent independent survey for their Interactive Response Technology software, IXRS 3.
Recognition
4G Clinical announced it ranked No. 159 on the Deloitte Technology Fast 500.
OKRA.ai won the Deloitte UK Fast 50 Women in leadership award and also ranked 9th in the Deloitte Technology Fast 500.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
